Emergent gets $23 million additional order for vaccine production

Comments Off on Emergent gets $23 million additional order for vaccine production
FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.

The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.

Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance.

Source: Read Full Article

Related posts:
  1. Pfizer says South African variant could significantly reduce protective antibodies
  2. England will ease lockdown restrictions in five week intervals: Sky News
  3. New York officials downplay concern over new coronavirus variant
  4. diclofenac gel side effects